BIONXT SOLUTIONS INC (BXT.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:BXT - CA0909741062 - Common Stock
BXT.DE Key Statistics, Chart & Performance
The current stock price of BXT.DE is 0.319 EUR. In the past month the price decreased by -23.13%. In the past year, price increased by 11.93%.
BXT.DE Technical Analysis
BXT.DE Financial Highlights
Over the last trailing twelve months BXT.DE reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS increased by 10.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -503.75% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BXT.DE Forecast & Estimates
BXT.DE Ownership
About BXT.DE
Company Profile
BioNxt Solutions, Inc. engages in the business of producing, extracting, and selling medical cannabis. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2019-08-06. The firm focuses on drug delivery platforms, diagnostic screening systems, and active pharmaceutical ingredient development. Its proprietary platforms include sublingual thin films, transdermal patches, oral tablets, and a new targeted chemotherapy platform. The targeted chemotherapy platform is designed to transform the way cytotoxic drugs are administered, by delivering active compounds directly into tumor tissue while minimizing exposure to healthy cells. Its product pipeline includes BNT23001, BNT23002, BNT24002, BNT24003, and BNT24004. BNT23001 is a sublingual Cladribine film targeting multiple sclerosis (MS), offering improved bioavailability and patient convenience. BNT23002 is a sublingual Cladribine formulation for myasthenia gravis (MG), addressing the challenges of oral medication in patients with swallowing difficulties. BNT24002 is a sublingual thin film for the treatment of lupus nephritis (LN).
Company Info
BIONXT SOLUTIONS INC
Suite 270 - 1820 Fir Street
Vancouver BRITISH COLUMBIA CA
Employees: 0
Phone: 17808186422
BIONXT SOLUTIONS INC / BXT.DE FAQ
Can you describe the business of BIONXT SOLUTIONS INC?
BioNxt Solutions, Inc. engages in the business of producing, extracting, and selling medical cannabis. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2019-08-06. The firm focuses on drug delivery platforms, diagnostic screening systems, and active pharmaceutical ingredient development. Its proprietary platforms include sublingual thin films, transdermal patches, oral tablets, and a new targeted chemotherapy platform. The targeted chemotherapy platform is designed to transform the way cytotoxic drugs are administered, by delivering active compounds directly into tumor tissue while minimizing exposure to healthy cells. Its product pipeline includes BNT23001, BNT23002, BNT24002, BNT24003, and BNT24004. BNT23001 is a sublingual Cladribine film targeting multiple sclerosis (MS), offering improved bioavailability and patient convenience. BNT23002 is a sublingual Cladribine formulation for myasthenia gravis (MG), addressing the challenges of oral medication in patients with swallowing difficulties. BNT24002 is a sublingual thin film for the treatment of lupus nephritis (LN).
What is the current price of BXT stock?
The current stock price of BXT.DE is 0.319 EUR.
What is the dividend status of BIONXT SOLUTIONS INC?
BXT.DE does not pay a dividend.
What is the ChartMill technical and fundamental rating of BXT stock?
BXT.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Which stock exchange lists BXT stock?
BXT.DE stock is listed on the Frankfurt Stock Exchange exchange.
Should I buy BXT stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BXT.DE.
What is BIONXT SOLUTIONS INC worth?
BIONXT SOLUTIONS INC (BXT.DE) has a market capitalization of 36.17M EUR. This makes BXT.DE a Nano Cap stock.